Kamada Ltd.

KMDA Healthcare Drug Manufacturers Specialty & Generic

Kamada Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $180.5 million, up 12.1% from fiscal 2024. In the quarter to June 2026, revenue grew 22.7%, EPS grew 23.1%, free cash flow grew 165.7% and total debt fell 38.8%, each against the same quarter a year earlier. Revenue growth for three consecutive years.

7.77 0.06 −0.77%
Market cap
$451.7M
P/E
20.4×
Fwd P/E
0.0×
Dividend yield
5.41%
F-score
7/9
Altman Z
3.33
Beneish M
−2.35
Dividend safety
50/100
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

7.86% 7.64% 7.97% 8.40%
Piotroski F-Score
7 7 7 7
ROA
5.61% 5.38% 5.37% 5.92%
ROIC
8.51% 8.06% 8.06% 8.47%
Return on Tangible Assets
11.17% 10.80% 11.26% 11.49%
Average Days of Receivables
73.77 66.06 81.67 80.98
Free Cash Flow per Share
0.31 0.27 0.28 0.45
Free Cash Flow
18.34 15.65 16.36 26.32
Other line items

Show all line items

Columns are period end dates